Orthofix Medical Inc. is a medical device and biological products company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. The company is headquartered in Lewisville, Texas.
| Revenue (TTM) | $833.19M |
| Gross Profit (TTM) | $593.73M |
| EBITDA | $20.93M |
| Operating Margin | -3.26% |
| Return on Equity | -13.90% |
| Return on Assets | -2.74% |
| Revenue/Share (TTM) | $20.68 |
| Book Value | $10.54 |
| Price-to-Book | 0.87 |
| Price-to-Sales (TTM) | 0.46 |
| EV/Revenue | 0.606 |
| EV/EBITDA | 26.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 3.80% |
| Shares Outstanding | $40.42M |
| Float | $40.41M |
| % Insiders | 2.17% |
| % Institutions | 95.76% |
Volatility is currently expanding
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Orthofix Medical Inc. (NASDAQ: OFIX) concerning possible breaches of fiduciary duties. If you are a current shareholder of OFIX, you can request additional information here: https://zlk.com/cases/orthofix-medical-inc-class-action-lawsuit-ofix-2 or contact Joseph E.
Orthofix Medical NASDAQ: OFIX reported second-quarter results that management said reflected improving operating trends across several businesses, while continued weakness among smaller U.S. spine distributors remained a headwind. The company reiterated its focus on commercial productivity, disciplined investment and profitable growth rather than pursuing revenue growth at any cost.
Orthofix Medical Inc. (OFIX) Q2 2026 Earnings Call Transcript
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Orthofix (OFIX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.13 per share a year ago.
Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
The average of price targets set by Wall Street analysts indicates a potential upside of 33.3% in Orthofix (OFIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The Johnson & Johnson, Pacira BioSciences and Orthofix executive takes charge of commercial execution as adoption of Canopus by eXeX accelerates across hospital systems in the United States and United Kingdom, and as eXeX launches Canopus Command, the first portal to give hospital leadership a live operational view into step-by-step execution of every surgical case. ORLANDO, Fla.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OFIX and any ticker you trade — then tracks every position and per-strategy win rate.
